Analyst Reco. Lavipharm S.A.

Equities

Delayed Athens S.E. Other stock markets 05:08:31 2024-05-22 am EDT			5-day change	1st Jan Change
0.968 ^EUR	-1.22%		+1.26%	+21.61%

Feb. 28	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	CI

No results for this search